Abbott Laboratories (ABT) Rated Buy as Benchmark Highlights Diagnostics Growth and Global Resilience

Abbott Laboratories (NYSE:ABT) ranks among the best medical device stocks to invest in. Benchmark began coverage of Abbott Laboratories (NYSE:ABT) on October 10 with a $145 price target and a Buy rating, describing the company as a reliable performer in a dynamic global environment. The firm claims that Abbott’s business strategy is unique in that it is not reliant on any one treatment, product, or market.

Benchmark anticipates that Abbott’s Diagnostics business will pick up speed again in 2026 with the introduction of a new molecular nucleic acid testing platform for blood screening, even if the company is still recuperating from post-pandemic drops in COVID-19 testing and value-based procurement pressures in China.

Additionally, Benchmark emphasized Abbott’s resilience to potential trade disruptions by pointing to its $500 million investment in new U.S. facilities and expansions for the upcoming year. According to analysts, this move puts the company in a strong position for any upcoming tariff talks.

Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items.

While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.